Clinical Trial: A Study of Pitolisant in Participants With Prader-Willi Syndrome

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07219485) titled 'A Study of Pitolisant in Participants With Prader-Willi Syndrome' on Oct. 20.

Brief Summary: The purpose of this study is to assess safety of pitolisant in eligible participants with Prader-Willi syndrome (PWS) who completed the End of Treatment (EOT) visit in a parent study (HBS-101-CL-002 [Open Label Extension (OLE)], HBS- 101-CL-004, or HBS-101-CL-312 OLE).

Study Start Date: Aug. 20

Study Type: INTERVENTIONAL

Condition: Prader-Willi Syndrome

Intervention: DRUG: Pitolisant

* Pitolisant 4.45 mg tablets

* Pitolisant 17.8 mg tablets

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: Harmony Biosciences Management, Inc.

P...